Clinicopathological features of fast eGFR decliners among patients with diabetic nephropathy

Kengo Furuichi,1 Miho Shimizu,2 Masayuki Yamanouchi,3 Junichi Hoshino,3 Norihiko Sakai,2 Yasunori Iwata,2 Tadashi Toyama,2 Shinji Kitajima,2 Akinori Hara,2 Yukio Yuzawa,4 Hiroshi Kitamura,5 Yoshiki Suzuki,6 Hiroshi Sato,7 Noriko Uesugi,8 Yoshihiko Ueda,9 Shinichi Nishi,10 Tomoya Nishino,11 Kenichi Samejima,12 Kentaro Kohagura,13 Yugo Shibagaki,14 Hirofumi Makino,15 Seiichi Matsuo,16 Yoshifumi Ubara,3 Hitoshi Yokoyama,1 Takashi Wada2

ABSTRACT

Introduction The speed of declining kidney function differs among patients with diabetic nephropathy. This study was undertaken to clarify clinical and pathological features that affect the speed of declining kidney function in patients with diabetic nephropathy.

Research design and methods This study was design as multicenter retrospective study. The subjects (377 patients with diabetic nephropathy diagnosed by kidney biopsy at 13 centers in Japan) were classified into three groups based on the estimated glomerular filtration rate (eGFR) declining speed. The eGFR increasing group, the control group, and the eGFR declining group were divided at 0 and 5 mL/min/1.73 m2/year, respectively. Characteristics of clinicopathological findings of declining kidney function were evaluated.

Results The mean observation period of this study was 6.9 years. The control group, the eGFR increasing group, and the eGFR declining group included 81, 66, and 230 patients, respectively. The incidences of composite kidney events represented by 100 persons/year were 25.8 in the eGFR declining group and 2.0 in the eGFR increasing group. After adjustment for age, sex, systolic blood pressure, hemoglobin, and urinary albumin levels, three clinicopathological findings (urinary albumin levels, presence of nodular lesion, and mesangiolysis) were risk factors for inclusion in the eGFR declining group (the ORs were 1.49, 2.18, and 2.08, respectively). In contrast, the presence of subendothelial space widening and polar vasculosis—were characteristic features of patients with rapidly declining kidney function after kidney biopsy.

The incidences of composite kidney events (new-onset ESRD, reduction of eGFR by ≥50%, or doubling of the serum creatinine level) in the eGFR declining group were more than 10 times higher than that in the eGFR increasing group.

Conclusions As well as urinary albumin elevation, nodular lesion and mesangiolysis were characteristic pathological features of patients with fast declining kidney function.

INTRODUCTION

The speed of declining kidney function differs among patients with diabetic nephropathy.1-3 There are two characteristic groups: “rapid decliners” and “no or slow decliners”.4-6 In addition, some patients recover kidney function.4 Fast decliners exhibit fast reduction in kidney function and reach end-stage renal disease (ESRD) in a short period of time, whereas slow decliners preserve a degree of kidney function for an extended period of

Significance of this study

What is already known about this subject?
- Some part of diabetic cases exhibit rapid reduction in kidney function and reach end-stage renal disease (ESRD) in a short period of time, and they are called “rapid eGFR decliner”.
- Although many clinical studies have been performed regarding kidney prognosis in patients with diabetic nephropathy, the pathological features of rapid decliners have not been fully elucidated.

What are the new findings?
- This study revealed that as well as urinary albumin elevation, two pathological findings—nodular lesion and mesangiolysis—were characteristic features of patients with rapidly declining kidney function.
- Two pathological findings—subendothelial space widening (or duplication of basement membrane) and polar vasculosis—were characteristic features of patients who could recover their kidney function after kidney biopsy.

How might these results change the focus of research or clinical practice?
- Among the various pathological changes in diabetic kidney disease (DKD), this study clarifies the important pathogenic prognosis features in rapid eGFR decliner, and these features should be therapeutic target for DKD.
- This study also will give a clue to detect good biomarkers associated with characteristic pathogenic change in rapid eGFR decliner.
time. Advanced proteinuria is a key clinical factor in the detection of fast decliners. Although the reduction of kidney function is usually followed by massive proteinuria, some patients show progressive kidney dysfunction with low-grade proteinuria. Therefore, further factors in addition to proteinuria are required. Although many clinical studies have been performed regarding kidney prognosis and cardiovascular events in patients with diabetic nephropathy, the pathological features of fast decliners have not been fully elucidated.

In recent years, many patients have been diagnosed with diabetic kidney disease without kidney biopsy assessment. However, pathological evaluation should be essential to understand and recognize the specific disease condition and activity of each patient. In many countries, the accumulation of evidence for diabetes treatment and the use of new drugs has enabled patients with diabetes to achieve glycemic control. Moreover, various medication, including renin/angiotensin system inhibitors, modified the levels of proteinuria and clinical manifestation. Furthermore, hypertension, dyslipidemia, aging, and other factors modify pathological progression in diabetic kidney disease. These various conditions would make it difficult to speculate the disease progression status. Therefore, pathological assessment in addition to clinical parameters, including proteinuria, should be required to understand the disease condition and activity of each patient. We previously reported differences and similarities between patients with diabetic nephropathy and patients with hypertensive nephrosclerosis. Moreover, we have reported the importance of histological analysis in addition to clinical stage to predict the kidney prognosis or cardiovascular events in patients with diabetic nephropathy. From this perspective, pathological evaluation of diabetic patients is of considerable value.

Because many patients are diagnosed with diabetic nephropathy, it is impossible to provide uniform and intensive care of all affected patients. Therefore, there is a need to identify patients at high risk of progressive kidney dysfunction and to closely monitor these patients. In the present study, we aimed to clarify the clinical and pathological features of patients with fast declining kidney function, as well as patients who exhibited recovery of kidney function. This analysis revealed that urinary albumin elevation and two pathological findings—nodular lesion and mesangiolysis—were characteristic features of patients with fast declining kidney function. Moreover, two pathological findings—subendothelial space widening (or duplication of basement membrane) and polar vasculosis—were characteristic features of patients who exhibited recovery of kidney function.

**METHODS**

**Study design and study population**

This study was designed as multicenter retrospective study. The subjects were 600 patients who had been diagnosed with diabetic nephropathy by kidney biopsy during the period from January 1, 1985 to December 31, 2016; samples were collected by our study group of the Ministry of Health, Labour and Welfare, as well as the Agency for Medical Research and Development in Japan. Data regarding 377 patients for whom the reduction of kidney function could be calculated using follow-up data for 3 years after kidney biopsy, and who had estimated glomerular filtration rate (eGFR) \( > 15 \) mL/min/1.73 m\(^2\), were analyzed in this study. The indications for biopsy were kidney function impairment and urinary abnormalities, such as albuminuria, proteinuria, hematuria, or abnormal casts in urine. Patients were excluded if they had a diagnosis of concomitant kidney disease with diabetic kidney disease and/or if they underwent protocol kidney transplant biopsy. Type 2 diabetes was defined as having diabetes onset after age 30 years and not taking insulin at the initial visit in our hospitals.

The patients were classified into three groups based on the rate of decline in kidney function. In accordance with KDIGO guidelines’ definition of progression, a rate of eGFR decline exceeding 5 mL/min/year was used as a cut-off. Thus, the control group was defined as \( \geq 5 \) mL/min/1.73 m\(^2\)/year in mean eGFR decline within 3 years after kidney biopsy; the eGFR increasing within 3 years after biopsy group (eGFR increasing group) was defined as \( < 0 \) mL/min/1.73 m\(^2\)/year in mean eGFR decline within 3 years after kidney biopsy; and the eGFR declining within 3 years after biopsy group (eGFR declining group) was defined as \( \geq 5 \) mL/min/1.73 m\(^2\)/year in mean eGFR decline within 3 years after kidney biopsy. The control group included 81 patients, the eGFR increasing group included 66 patients and the eGFR declining group included 230 patients. We compared the control group with the eGFR increasing and eGFR declining groups. Clinical data were used at the time of kidney biopsy and clinical follow-up. Histological evaluations were performed in accordance with the method used in a previous paper. Clinically required biopsy samples were used. Under the approval of the ethics committee of Kanazawa University, the opt-out approach is used in this study. Moreover, this study was conducted in accordance with Declaration of Helsinki.

**Pathological examinations**

Biopsy samples were stained with periodic acid–Schiff reagent, periodic acid–methenamine silver, H&E, and Mallory–Azan or Masson’s Trichrome stains, then examined by light microscopy. In accordance with a previous study, nine glomerular lesions, two interstitial lesions, and two vascular lesions were evaluated in each biopsy sample. The scoring system is as follows: nine glomerular lesions (diffuse lesion (grades 0–3); nodular lesion (grades 0–1); subendothelial space widening (grades 0–3); exudative lesion (grades 0–1); mesangiolysis/microaneurysm (grades 0–1); perihilar neovascularization (grades 0–1); global glomerulosclerosis, collapsing glomerulopathy, and ischemic nephropathy (grades 0–1); segmental sclerosis (grades 0–1); glomerulomegaly (grades 0–1)), two interstitial lesions (interstitial fibrosis...
and tubular atrophy (grades 0–3) and interstitial cell infiltration (grades 0–3), and two vascular lesions (arteriolar hyalinosis (grades 0–3) and intimal thickening (grades 0–3)). We also evaluated the percent glomerular sclerosis as defined by the number of total global and segmental sclerotic glomeruli per total number of glomeruli. Pathologists in each center performed all pathological scoring in this study.

Clinical data
Age, sex, body mass index, systolic blood pressure, diastolic blood pressure, hemoglobin (Hb) A1c, and total cholesterol were used as baseline clinical parameters at the time of the kidney biopsy. eGFR was calculated using the following formula: eGFR (mL/min/1.73 m²)=194×serum creatinine−1.094×age−0.287.

(For female patients, this value was multiplied by 0.739.)

HbA1c levels were recorded as national glycohemoglobin standardization program values, in accordance with the recommendations of the Japanese Diabetic Society and the International Federation of Clinical Chemistry.

Outcomes
The primary outcome of this study was composite kidney events, which were defined as new-onset ESRD, reduction of eGFR by ≥50%, or doubling of the serum creatinine level. ESRD was defined as initiation of hemodialysis/peritoneal dialysis, renal transplantation, or death as a result of uremia. The secondary outcomes for this study were kidney death (hemodialysis/peritoneal dialysis, renal transplantation, or death as a result of uremia), cardiovascular events (cardiovascular death, nonfatal myocardial infarction, coronary intervention, or nonfatal stroke), and all-cause mortality. The sources of the outcome data were collected from the medical records of each center. Patients who did not reach the outcome of interest or who were lost to follow-up were censored at their last follow-up visit.

Statistical analysis
Data are expressed as mean±SD or median (IQR). Continuous variables were compared between groups using the Mann-Whitney U test for nonparametric data; categorical variables were compared between groups using the χ² test. To minimize the clinical background difference between groups, propensity score method was used. Patients’ background characteristics, including urinary albumin, Hb, and systolic blood pressure, were balanced in the analysis. Cox regression analysis was used to calculate adjusted HRs for each outcome. Survival curves were obtained using Kaplan-Meier analysis and compared using the log-rank test. Univariate and multivariate logistic regression models were used to analyze factors for eGFR declining and eGFR increasing groups. All analyses were conducted using Stata V.13 (StataCorp, College Station, TX, USA). A two-sided p value of <0.05 was considered statistically significant.

RESULTS
Background of clinical manifestations in each group
The eGFR increasing, control, and eGFR declining groups included 66, 81, and 230 patients, respectively (online supplementary figure 1). The mean observation period of this study was 6.9 years. The median baseline eGFR in the eGFR increasing group was 53.9 mL/min/1.73 m², whereas it was 50.2 mL/min/1.73 m² in the control group; conversely, the median baseline eGFR in the eGFR declining group was 47.3 mL/min/1.73 m².

Table 1 summarizes the clinical manifestations of the three groups. When comparing the eGFR increasing and eGFR declining groups with the control group, there were no differences in proportion of men, body mass index, diastolic blood pressure, eGFR, HbA1c level, or hematuria-positive rate. However, systolic blood pressure and urinary albumin levels increased among groups: eGFR increasing (lowest), control, and eGFR declining (highest). Serum levels of total protein and albumin decreased in the eGFR declining group, compared with the control group, as did the Hb level; serum levels of total cholesterol increased in the eGFR declining group, compared with the control group. Regarding medication usage, renin/angiotensin system inhibitors were less frequently used in the eGFR increasing group. Systolic and diastolic blood pressures, as well as serum total protein, serum albumin, and urinary protein levels were strongly correlated (online supplementary table 1). In terms of clinical classification, approximately 60% of patients were classified into chronic kidney disease Category Red, and approximately 80% of patients were stage 3 of diabetic nephropathy based on the Japanese classification 2014 (online supplementary table 2, online supplementary figure 2).

Clinical outcomes in each group
The incidences of composite kidney events and kidney deaths, represented by 100 persons/year, were 25.8 and 3.0 in the eGFR declining group, respectively. In contrast, the incidences of those outcomes were 2.0 and 0.2 in the eGFR increasing group (online supplementary table 3). Both incidence rates were approximately 10 times higher in the eGFR declining group than in the eGFR increasing group. Moreover, respective rates of death and cardiovascular events were 2.9 and 3.3 in the eGFR declining group, whereas they were 1.7 and 1.1 in the eGFR increasing group. After adjustment for age, sex, urinary albumin level, Hb and systolic blood pressure, the adjusted HRs for composite kidney events in Cox analysis were 3.05 and 0.31 in the eGFR declining and eGFR increasing groups, respectively (figure 1). The adjusted HR for all-cause mortality was also high in the eGFR declining group (figure 1). The survival curve of composite kidney events in each of the three groups.
### Table 1  Baseline clinical characteristics stratified by eGFR declining speed

|                     | Increasing (n=66) | Control (n=81) | Decreasing (n=230) | Total | Inc vs Cont | Dec vs Cont |
|---------------------|------------------|---------------|-------------------|-------|------------|------------|
| **Age (years old)** | Median 56 47 63  | Median 60 53 66 | Median 60 50 67   | 59 51 66 | <0.05      |            |
| **Gender (male)**   | 69.7%            | 72.8%         | 71.7%             | 71.6% |            |            |
| **BMI**             | 22.7 20.8 25.4  | 23.4 21.6 25.8 | 23.0 21.2 25.5   |       |            |            |
| **SysBP (mm Hg)**   | 134 123 146      | 140 130 155   | 148 138 162       | 142 132 160 | <0.05 | <0.01     |
| **DiaBP (mm Hg)**   | 73 70 84         | 80 70 87      | 80 72 90          |       |            |            |
| **Hb (g/dL)**       | 13.4 11.9 15.2  | 12.8 11.3 14.4| 11.6 10.0 13.2   | 12.2 10.5 13.9 | <0.01 |            |
| **eGFR (mL/min/1.73 m²/year)** | 53.9 38.8 70.6 | 50.2 31.7 65.5 | 47.3 35.0 66.0   | 49.1 35.0 66.4 | <0.01 |            |
| **UA (mg/dL)**      | 6.0 5.2 7.4      | 6.7 5.8 7.5   | 6.5 5.7 7.6       | 6.5 5.6 7.6 | <0.01 |            |
| **TP (g/dL)**       | 7.0 6.5 7.7      | 6.8 6.1 7.1   | 6.0 5.4 6.8       | 6.3 5.6 7.0 | <0.01 |            |
| **Alb (g/dL)**      | 3.8 3.4 4.3      | 3.6 2.9 4.0   | 3.0 2.5 3.5       | 3.2 2.6 3.7 | <0.01 |            |
| **HbA1c (%)**       | 7.6 6.5 8.8      | 7.2 6.4 8.5   | 7.0 6.0 8.9       | 7.2 6.2 8.8 | <0.01 |            |
| **Tcho (mg/dL)**    | 193 159 226      | 194 165 229   | 211 179 256       | 206 175 244 | <0.01 |            |
| **LDL (mg/dL)**     | 120 102 173      | 135 106 168   | 133 102 160       | 132 102 162 | <0.01 |            |
| **TG (mg/dL)**      | 156 103 219      | 158 107 195   | 153 114 210       | 154 110 207 | <0.01 |            |
| **Ualb (g/day)**    | 0.4 0.1 0.9      | 0.6 0.2 1.3   | 2.0 0.9 3.4       | 1.2 0.5 2.6 | <0.05 | <0.01     |
| **UOB**             | 14.5%            | 20.7%         | 42.0%             | 32.7% |            |            |
| **ACEI**            | 25.0%            | 32.5%         | 33.6%             | 32.3% |            |            |
| **ARB**             | 21.4%            | 55.0%         | 53.7%             | 49.8% | <0.01 |            |
| **RAS**             | 46.4%            | 87.5%         | 87.2%             | 82.0% | <0.05 |            |
| **CCB**             | 50.0%            | 60.0%         | 49.7%             | 51.6% |            |            |
| **Lipid**           | 17.9%            | 20.0%         | 28.2%             | 25.3% |            |            |

Data are median (25th, 75th percentile) or percentage unless otherwise indicated.

ACEI, ACE inhibitor; Alb, albumin; ARB, angiotensin II receptor blocker; BMI, body mass index; CCB, calcium channel blocker; Cont, control group; Dec, eGFR declining group; DiaBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; Inc, eGFR increasing group; LDL, low-density-lipoprotein cholesterol; lipid, lipid-lowering agent; RAS, renin-angiotensin-aldosterone system blocker; SysBP, systolic blood pressure; Tcho, total cholesterol; TG, triglyceride; TP, total protein; UA, uric acid; UAlb, urinary albumin; UOB, urinary occult blood.
Figure 1  Crude and adjusted HR for composite kidney event, kidney death, and all-cause death, among three groups by eGFR declining speed. Cox analysis indicated that eGFR increasing group and eGFR declining group were statistically significantly high and low risk for composite kidney event even after adjusted by age, gender, urinary albuminuria, Hb, and systolic pressure, respectively (control group is reference). Similarly, eGFR declining group was statistically significantly high risk for all-cause death even after adjusted by age, gender, urinary albuminuria, Hb, and systolic pressure. eGFR, estimated glomerular filtration rate; Hb, hemoglobin; OR, odds ratio; CI, confidence interval. Figure 2  Survival curves for composite kidney end points stratified by three groups as derived from the Kaplan-Meier method with log-rank test. Event-free curves of composite kidney end points are shown. Differences between two groups were compared by a log-rank test. Figure 3  Crude and adjusted HR for kidney death. Crude and adjusted HR for kidney death were determined for various pathological clinical characteristics (indicated in the figure) by the Cox analysis. A plot of the HR for each variable is shown; open circles indicate the HR in univariate analysis, and solid circles indicate the HR in multivariable analysis with age, gender, urinary levels of albumin, and hemoglobin; 95% CI shown as whiskers. HRs were calculated for a one score increase in each pathological finding; 10% increase in global glomerulosclerosis; 1 g/day increase in urinary levels of albumin; 1 g/dL increase in Hb. Athero, intimal thickening; Diff, diffuse lesion; Double, subendothelial space widening (or duplication of basement membrane); Exda, exudative lesion; GScl, global glomerulosclerosis, collapsing glomerulopathy, and ischemic nephropathy; Hb, hemoglobin; ICell, interstitial cell infiltration; IFTA, interstitial fibrosis and tubular atrophy; MesL mesangiolysis/microaneurysm; Nodu, nodular lesion; UAlb, urinary levels of albumin.

Pathological changes in each group

The incidence of each pathological finding increased as follows: eGFR increasing group (lowest), control group, and eGFR declining group (highest) (table 2, online supplementary figure 4). However, after adjustment using a propensity score matching system with Hb, systolic

in the eGFR increasing group, >50% of patients had no composite kidney events within 20 years after kidney biopsy. Kidney death showed a similar pattern to that of composite kidney events (online supplementary figure 3). In addition to the Kaplan-Meier analysis, crude and adjusted HR for kidney death were evaluated by the Cox analysis (figure 3). Seven glomerular and interstitial pathological changes, including exudative lesion, mesangiolysis, nodular lesion, and interstitial fibrosis, and two clinical data, including urinary albumin levels and anemia levels, were detected as risk factors for kidney death in multivariable analysis adjusted for age, gender, urinary levels of albumin, and hemoglobin.
### Table 2  Baseline pathological characteristics stratified by eGFR declining speed

|                | Increasing Mean | Increasing Median | Inc vs Cont P value | Control Mean | Control Median | Dec vs Cont P value | Decreasing Mean | Decreasing Median | Total Mean | Total Median | 25 75 P value | 25 75 P value |
|----------------|-----------------|-------------------|---------------------|--------------|----------------|---------------------|-----------------|-------------------|------------|--------------|---------------|---------------|
| Diff           | 1.72            | 2                 |                     | 2.11         | 2             |                     | 2.32            | 3                 | 2.17       | 2            | 1             | 3            |
| Nodu           | 0.20            | 0                 |                     | 0.30         | 0             |                     | 0.53            | 1                 | 0.43       | 0            | 0             | 1            |
| Double         | 0.43            | 0                 |                     | 0.89         | 1             |                     | 1.21            | 1                 | 1.00       | 1            | 0             | 2            |
| Exda           | 0.28            | 0                 |                     | 0.37         | 0             |                     | 0.58            | 1                 | 0.48       | 0            | 0             | 1            |
| MesL           | 0.16            | 0                 |                     | 0.25         | 0             |                     | 0.48            | 0                 | 0.38       | 0            | 0             | 1            |
| Pola           | 0.52            | 1                 |                     | 0.78         | 1             |                     | 0.79            | 1                 | 0.74       | 1            | 0             | 1            |
| GScle          | 16.80           | 10.0              |                     | 24.58        | 20.0          |                     | 27.28           | 24.0              | 24.85      | 20.0         | 6.3           | 39.0         |
| SSscle         | 1.79            | 0                 |                     | 2.90         | 0             |                     | 3.80            | 0                 | 3.26       | 0            | 0             | 4.3          |
| G Mega          | 0.30            | 0                 |                     | 0.38         | 0             |                     | 0.45            | 0                 | 0.41       | 0            | 0             | 1            |
| IFTA           | 1.27            | 1                 |                     | 1.65         | 2             |                     | 2.03            | 2                 | 1.82       | 2            | 1             | 3            |
| I Cell          | 0.92            | 1                 |                     | 1.27         | 1             |                     | 1.31            | 1                 | 1.23       | 1            | 1             | 2            |
| Hyal           | 1.91            | 2                 |                     | 2.30         | 3             |                     | 2.27            | 2                 | 2.21       | 3            | 1             | 3            |
| Ather          | 1.00            | 1                 |                     | 1.22         | 1             |                     | 1.31            | 2                 | 1.24       | 1            | 1             | 2            |

Data are mean and median (25th, 75th percentile) of pathological score or %.

Baseline pathological characteristics stratified by eGFR declining speed were shown. After propensity score matching with urinary albumin, Hb, and systolic blood pressure, three pathological findings (subendothelial space widening, global glomerulosclerosis, and interstitial cell infiltration) have a lower score in eGFR increasing group than control group. There was no statistical significance in any pathological financing between control and declining group. Athero, intimal thickening; Cont, control group; Dec, eGFR declining group; Diff, diffuse lesion; Double, subendothelial space widening (or duplication of basement membrane); eGFR, estimated glomerular filtration rate; Exda, exudative lesion; G Mega, glomerulomegaly; GScle, global glomerulosclerosis, collapsing glomerulopathy, and ischemic nephropathy; Hyali, arteriolar hyalinosis; I Cell, interstitial cell infiltration; IFTA, interstitial fibrosis and tubular atrophy; Inc, eGFR increasing group; MesL, mesangiolyis/microaneurysm; Nodu, nodular lesion; Pola, perihilar neovascularization (polar vasculosis); SSscle, segmental sclerosis.
blood pressure, and urinary levels of albumin, there were no statistical differences between the control and eGFR declining groups (table 2). Three pathological findings were significantly different between the eGFR increasing group and control groups even after matching: subendothelial space widening (or duplication of basement membrane), global sclerosis, and interstitial cell infiltration. These findings were confirmed when our cohort was divided into two groups by ≥5 mL/min/1.73 m²/year in mean eGFR decline within 3 years after kidney biopsy (online supplementary table 4). After adjustment using a propensity score matching system with Hb, systolic blood pressure; uAlb, urinary levels of albumin. 3 clinicopathological findings (urinary albumin levels, presence of nodular lesion, and presence of mesangiolysis) were risk factors for inclusion in the eGFR declining group; the ORs were 0.63 and 0.66, respectively. Moreover, the areas under the curve of polar vasculosis reduced the risk for inclusion in the eGFR increasing group, relative to the control group; the ORs were 0.53 and 0.41, respectively (figure 4B). When examining these four factors using receiver operating characteristic curve analysis, the areas under the curve of urinary level of albumin, the presence of nodular lesion, and the presence of mesangiolysis were 0.75, 0.62, and 0.61, respectively. Moreover, the areas under the curve of the presence of subendothelial space widening (or duplication of basement membrane) and the presence of polar vasculosis were 0.63 and 0.66, respectively. These findings were confirmed when our cohort was divided into two groups by ≥5 mL/min/1.73 m²/year in mean eGFR decline within 3 years after kidney biopsy (online supplementary figure 4). After adjustment for age, sex, systolic blood pressure, Hb levels, and urinary albumin levels, three clinicopathological findings (urinary albumin levels, presence of nodular lesion, and presence of mesangiolysis) were included in risk factors for inclusion in the eGFR declining group.

**DISCUSSION**

In this study, we aimed to elucidate the clinicopathological factors that contribute to fast declining kidney function. The clinical features of the group with fast declining kidney function were high urinary albumin, hypertension, and anemia. Analysis of pathological factors revealed that the presence of nodular lesions and mesangiolysis were independently associated with fast declining kidney function. Moreover, the eGFR increasing group had reduced incidences of the presence of polar vasculosis and the presence of subendothelial space widening (or duplication of basement membrane). These pathological changes might contribute to the different types of pathogenesis that characterize the progression of diabetic kidney disease.

Nodular lesions and mesangiolysis were independent pathological risk factors for fast declining kidney function. In our previous studies, patients with nodular lesions or mesangiolysis exhibited poor kidney prognosis, despite the absence of albuminuria. Moreover, there was a strong positive correlation between the presence of nodular lesions and the presence of mesangiolysis. Type VI collagen is reportedly accumulated in nodular lesions; this type of collagen is resistant to various intrinsic collagenases. Moreover, mesangiolysis is a typical pathological
change associated with reduction of the glomerular filtration surface in the glomerular capillary lumen. These pathological changes were expected to be predictive factors of declining kidney function and should be key targets for treatment of diabetic kidney disease. However, the mechanisms by which nodular lesions and mesangiolysis occur in patients with diabetic nephropathy are not yet clear. There are limited animal models of diabetic nephropathy with nodular lesions and mesangiolysis, thus, additional research is urgently needed.

Polar vasulosis and subendothelial space widening (or duplication of basement membrane) have other clinical impacts on declining kidney function. Importantly, these pathological findings were able to distinguish the eGFR increasing group and control groups. There have been only a few reports regarding the clinical significance of polar vasulosis. Polar vasulosis is expected to connect glomerular and peritubular capillaries. However, the details of its structure and function remain unclear. Moreover, subendothelial space widening (or duplication of basement membrane) is a pathological change due to glomerular capillary endothelial cell dysfunction. The frequency of these two pathological changes gradually increases in accordance with the progression of albuminuria and reduction of eGFR. However, we identified patients without these pathological findings, who comprised the eGFR increasing group. It is unclear whether patients who recovered their kidney function after kidney biopsy were resistant to glomerular capillary endothelial cell dysfunction or neovasulosis, or whether these two pathological changes were predictive of declining kidney function. These points will be clarified by future investigations. Basic research, including animal experiments, and prospective clinical studies with therapeutic interventions are needed to elucidate the mechanisms and pathogenic implications of nodular lesions, mesangiolysis, polar vasulosis, and subendothelial space widening (or duplication of basement membrane) in diabetic kidney disease.

The prediction of declining kidney function without pathological findings is an important goal. In this study, patients with declining kidney function showed abundant urinary albumin, hypertension, and low Hb levels, compared with patients in the control group; urinary albumin elevation was also identified as an independent risk factor for declining kidney function. Furthermore, approximately 80% of patients in the eGFR declining group had stage 3 diabetic nephropathy based on the Japanese classification (albuminuria of ≥300 mg/g Cr and eGFR of ≥30 mL/min/1.73 m²). Many studies have shown that albumin is a predictive factor for kidney prognosis; our data are consistent with those previous findings. The clinical indicators identified in this study should be valuable for identification of patients with fast declining kidney function and can enable close monitoring to prevent disease progression in those selected patients. Moreover, to detect good biomarkers associated with pathogenesis of the characteristic pathological change in patients with fast decliners should be valuable in clinical setting of follow-up the patient with diabetic kidney disease.

This study had some limitations. It was retrospective and therefore included many biases. Selective bias due to kidney biopsy was presumably the most influential bias in this study. Moreover, we used reduction in eGFR ≥5 mL/min/1.73 m²/year as a cut-off criterion for inclusion of patients in the eGFR declining group in this study; other cut-off criteria could have been selected. We observed that a cut-off criterion of reduction in eGFR ≥10 mL/min/1.73 m²/year yielded results similar to those described in this paper (data not shown). In addition, the analysis of therapeutic points was limited because there was limited information available regarding treatment in this data set. Prospective research with treatment intervention is necessary, as are validation studies in different cohorts.

Comparison of the three groups based on mean eGFR decline revealed two characteristic pathological changes: the presences of nodular lesion and mesangiolysis were predictive of fast declining kidney function, whereas the presences of subendothelial space widening (or duplication of basement membrane) and polar vasulosis were predictive of kidney function recovery. These are valuable new findings that reveal the underlying pathogenesis of diabetic kidney disease. These pathological changes could be targets for future biomarker development and therapeutic interventions.

Acknowledgements The authors thank Dr. Hiroshi Kida (National Hospital Organization Kanazawa Medical Center) for his helpful comments on this study.

Contributors The authors' responsibilities were as follows: KY, YUe, SM, and HM conceived the study, YY, HK, YSU, NU, YUb, SN, TN, KS, KK, HY, and YSh participated in the design and implementation of the study; YY, HK, YSU, NU, YUb, SN, TN, KS, KK, HY, and YSh participated in the data collection; YY, HK, YSU, NU, YUb, SN, TN, KS, KK, HY, and YSh performed the data analysis; YY, HK, YSU, NU, YUb, SN, TN, KS, KK, HY, and YSh participated in manuscript preparation; and YY, HK, YSU, NU, YUb, SN, TN, KS, KK, HY, and YSh contributed to the interpretation of data. All authors have read and approved the final version of the manuscript.

Author affiliations
1Department of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan
2Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan
3Nephrology Center, Toranomon Hospital, Tokyo, Japan
4Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan
5Department of Pathology, Clinical Research Center, National Hospital Organization Chiba-East National Hospital, Chiba, Japan
6Health Administration Center, Niigata University, Niigata, Japan
7Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan
8Department of Nephrology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
9Department of Pathology, Dokkyo Medical University, Saitama Medical Center, Koshigaya, Japan
10Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan
11Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan
12Department of Nephrology, Nara Medical University, Nara, Japan
13Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine, Naha, Okinawa, Japan
14Division of Nephrology, Department of Internal Medicine, St. Marianna University, School of Medicine, Kawasaki, Japan
15Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
16Division of Nephrology, Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

Pathophysiology/Complications

Author affiliations

1Department of Nephrology, Kanazawa Medical University School of Medicine, Uchinada, Japan
2Department of Nephrology and Laboratory Medicine, Faculty of Medicine, Institute of Medical, Pharmaceutical and Health Sciences, Graduate School of Medical Sciences, Kanazawa University, Kanazawa, Ishikawa, Japan
3Nephrology Center, Toranomon Hospital, Tokyo, Japan
4Department of Nephrology, Fujita Health University School of Medicine, Toyoake, Japan
5Department of Pathology, Clinical Research Center, National Hospital Organization Chiba-East National Hospital, Chiba, Japan
6Health Administration Center, Niigata University, Niigata, Japan
7Clinical Pharmacology and Therapeutics, Tohoku University Graduate School of Pharmaceutical Sciences, Sendai, Japan
8Department of Nephrology, Faculty of Medicine, Fukuoka University, Fukuoka, Japan
9Department of Pathology, Dokkyo Medical University, Saitama Medical Center, Koshigaya, Japan
10Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan
11Department of Nephrology, Nagasaki University Hospital, Nagasaki, Japan
12Department of Nephrology, Nara Medical University, Nara, Japan
13Department of Cardiovascular Medicine, Nephrology and Neurology, University of the Ryukyus School of Medicine, Naha, Okinawa, Japan
14Division of Nephrology, Department of Internal Medicine, St. Marianna University, School of Medicine, Kawasaki, Japan
15Department of Nephrology, Rheumatology, Endocrinology and Metabolism, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan
16Division of Nephrology, Department of Internal Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan

Acknowledgements The authors thank Dr. Hiroshi Kida (National Hospital Organization Kanazawa Medical Center) for his helpful comments on this study.
in the collection and statistical analysis of the data. MY, NS, YI, TT, SK, and AH participated in the interpretation of the results. KF, MS, JH, and HS drafted the manuscript. KF and TW critically reviewed the manuscript. All authors read and approved the final manuscript. KF and TW are the guarantors of this work and, as such, had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Funding This study was supported in part by a Grant-in-Aid for Diabetic Nephropathy and Nephrosclerosis Research from the Ministry of Health, Labour and Welfare of Japan and Grant-in-Aid for Practical Research Project for Renal Diseases, from the Japan Agency for Medical Research and Development (No. 15ek0310003h10001). This work was also supported in part by Grants-in-Aids from the Ministry of Education, Culture, Sports, Science, and Technology of the Japanese Government.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Prior ethical approval was obtained from the Medical Ethics Committee of Kanazawa University (Approval No. 1204).

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as online supplementary information.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the license their derivative works on different terms, provided the original work is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,

ORCID ids

Kengo Furuchi http://orcid.org/0000-0002-7069-0938
Masayuki Yamanoichi http://orcid.org/0000-0003-3264-9691

REFERENCES

1 Zoppini G, Targher G, Chonchol M, et al. Predictors of estimated GFR decline in patients with type 2 diabetes and preserved kidney function. Clin J Am Soc Nephrol 2012;7:401–8.
2 Barzilay JL, Lovato LF, Murray AM, et al. Albuminuria and cognitive decline in people with diabetes and normal renal function. Clin J Am Soc Nephrol 2013;8:1907–14.
3 Furuchi K, Shimizu M, Yuzawa Y, et al. Clinicopathological analysis of biopsy-proven diabetic nephropathy based on the Japanese classification of diabetic nephropathy. Clin Exp Nephrol 2018;22:570–82.
4 Lim CTS, Nordin NZ, Fadhlina NZ, et al. Rapid decline of renal function in patients with type 2 diabetes with heavy proteinuria: a report of three cases. BMC Nephrol 2019;20:22.
5 Krolewski AS, Skupien J, Rossing P, et al. Fast renal decline to end-stage renal disease: an unrecognized feature of nephropathy in diabetes. Kidney Int 2017;91:1300–11.
6 Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care 2015;38:954–62.
7 Nowak N, Skupien J, Smiles AM, et al. Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiologic studies and prognostic tests development. Kidney Int 2018;93:1198–206.
8 Oshima M, Toyama T, Haneda M, et al. Estimated glomerular filtration rate decline and risk of end-stage renal disease in type 2 diabetes. PLoS One 2018;13:e0201535.
9 Alicic RZ, Neumiller JJ, Johnson EJ, et al. Sodium-glucose cotransporter 2 inhibition and diabetic kidney disease. Diabetes 2019;68:248–57.
10 Neuen BL, Young T, Heerspink HJL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol 2019;7:845–54.
11 Nistala R, Savin V, Diabetes SV. Diabetes, hypertension, and chronic kidney disease progression: role of DPP4. Am J Physiol Renal Physiol 2017;312:F661–70.
12 Tripoposkiadis F, Xanthopoulos A, Butler J, et al. Cardiovascular aging and heart failure: JACC review topic of the week. J Am Coll Cardiol 2019;74:804–13.
13 Furuchi K, Shimizu M, Okada H, et al. Clinico-pathological features of kidney disease in diabetic cases. Clin Exp Nephrol 2018;22:1046–51.
14 Shimizu M, Furuchi K, Yokoyama H, et al. Kidney lesions in diabetic patients with normalalbuminuric renal insufficiency. Clin Exp Nephrol 2014;18:305–12.
15 Yanamouchi M, Furuchi K, Hoshino J, et al. Nonproteinuric versus proteinuric phenotypes in diabetic kidney disease: a propensity score-matched analysis of a nationwide, biopsy-based cohort study. Diabetes Care 2019;42:981–902.
16 Furuchi K, Yuzawa Y, Shimizu M, et al. Nationwide multicentre kidney biopsy study of Japanese patients with type 2 diabetes. Nephrol Dial Transplant 2018;33:138–48.
17 Shimizu M, Furuchi K, Toyama T, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care 2013;36:3655–62.
18 Chapter 2: definition, identification, and prediction of CKD progression. Kidney Int Suppl 2013;3:63–72.
19 Haneda M, Utsunomiya K, Koya D, et al. A new classification of diabetic nephropathy 2014: a report from joint committee on diabetic nephropathy. Clin Exp Nephrol 2015;19:1–5.
20 Wada T, Shimizu M, Yokoyama H, et al. Nodular lesions and mesangiolysis in diabetic nephropathy. Clin Exp Nephrol 2013;17:3–9.
21 Furuchi K, Hisada Y, Shimizu M, et al. Matrix metalloproteinase-2 (MMP-2) and membrane-type 1 MMP (MT1-MMP) affect the remodeling of glomerulosclerosis in diabetic OLETF rats. Nephrol Dial Transplant 2011;26:3124–31.
22 Saito Y, Kida H, Takeda S, et al. Mesangiolysis in diabetic glomeruli: its role in the formation of nodular lesions. Kidney Int 1988;34:389–96.
23 Mise K, Ueno T, Hoshino J, et al. Nodular lesions in diabetic nephropathy: collagen staining and renal prognosis. Diabetes Res Clin Pract 2017;127:187–97.
24 Okada T, Nagao T, Matsumoto H, et al. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrol Dial Transplant 2012;27:88–75.
25 Inagi R, Yamamoto Y, Nanakaku M, et al. A severe diabetic nephropathy model with early development of nodule-like lesions induced by megsin overexpression in RAGE/INOS transgenic mice. Diabetes 2006;55:356–66.
26 Nyumura I, Honda K, Tanabe K, et al. Early histologic lesions and risk factors for recurrence of diabetic kidney disease after kidney transplantation. Transplantation 2012;94:612–9.
27 Hoshino J, Furuchi K, Yamanoouchi M, et al. A new pathological scoring system by the Japanese classification to predict renal outcome in diabetic nephropathy. PLoS One 2018;13:e0190923.
28 Yamakawa T, Kawaguchi T, Kitamura H, et al. Glomerular basement membrane duplication is a predictor of the progression of diabetic nephropathy in patients with type 2 diabetes. Clin Exp Nephrol 2019;23:521–9.
29 Maciasac RJ, Ekinici EJ, Jerums G, et al. Progressive diabetic nephropathy. How useful is microalbuminuria?: contra. Kidney Int 2014;86:50–7.
30 Pena MJ, de Zeeuw D, Mitsch H, et al. Prognostic clinical and molecular biomarkers of renal disease in type 2 diabetes. Nephrol Dial Transplant 2015;30 Suppl 4:v86–95.
31 Norris KC, Smoyer KE, Rolland C, et al. Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review. BMC Nephrol 2018;19:36.